Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia.

Nat Commun · 2025 · PMC12019388 · PMID 40268927

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Upon termination 83 days post-LSC injection, the CLL-1 + group showed a trend towards higher engraftment (Supplementary Fig. 15D ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.